| Product Unit Size | Cost | Quantity | Stock |
|---|
LOXO-101 (larotrectinib) is an inhibitor of tropomyosin kinase receptors TRKA, TRKB, and TRKC. It exhibits strong antitumor activity in TRK fusion-positive cancers. In TRK fusion-positive cancers, NTRK genes which are responsible for encoding TRK are fused, leading to the transcription of chimeric TRK proteins with overexpressed kinase function.
| Cas No. | 1223403-58-4 |
|---|---|
| Purity | ≥99% |
| Formula | C21H22F2N6O2 |
| Formula Wt. | 428.44 |
| Chemical Name | Larotrectinib |
| IUPAC Name | (3S)-N-{5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide |
| Synonym | LOXO 101, LOXO101, ARRY 470, ARRY-470, ARRY470, Larotrectinib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Drilon A., Laetsch T., et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 378(8):731-739 (2018). PMID: 29466156.
